Preferred segments of neural thread protein and method of using the same

ABSTRACT

The invention is directed to preferred repeat sequences of Neural Thread Protein (NTP), peptides, mimetics, antibodies, and nucleic acids of the preferred sequences, and diagnostic and therapeutic methods of using such preferred NTP sequences.

CROSS REFERENCE TO RELATED APPLICATION

This application is a Divisional of U.S. application Ser. No. 09/697,590filed on Oct. 27, 2000.

FIELD OF THE INVENTION

The present invention is directed to preferred segments of neural threadprotein useful in, for example, binding assays, protein and antibodypurification, therapeutics, and diagnostics.

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) is a presently incurable neurodegenerativedisease affecting at least 12 million people worldwide. AD ispredominantly a disease of the elderly, with a rate of incidence ofabout 1% of those aged 65 and rising to an estimated 40% by age 85. Asthe population as a whole grows older, because of medical advances,increasing life expectancies, and aging of the baby boomer generation,the overall incidence of AD is expected to rise and present even more ofa burden to heath care systems and to patients and their caregivers andfamily.

No effective treatment of AD exists today. Currently availabletreatments such as Aricept® (donepezil HCl; Pfizer Corp.), Exelon®(rivastigmine tartrate; Novartis Pharmaceuticals Corp.) and Cognex®(tacrine; Warner Lambert Corp.) are intended to provide a measure ofsymptomatic relief for patients with mild to moderate AD and do notaddress the causes of the disease.

Clinical diagnosis of AD is also imperfect; accuracy varies from roughly50-60% for general practitioners to 80-90% for Alzheimer's diseasespecialists at referral centers (Molsa et al., J. Neurol. Neurosurg.Psychiatry, 48 (11):1085-90 (1985); Rocca et al., Ann. Neurol.,19:415-424 (1986); Burns et al., BMJ, 301(6759):1026 (1990); Risse etal., Am. J. Psychiatry, 147(2):168-72 (1990); Gilleard et al., ActaPsychiatr. Scand., 85(4):264-9 (1992); Mendez et al., Alzheimer Dis.Assoc. Disord., 6:35-43 (1992); Fleming et al., Mayo Clin. Proc.,7:1093-1107 (1995); Corey-Bloom et al., Neurology, 45:211-218 (1995);and Bowler et al., J. Neurol. Neurosurg. Psychiatry, 64(1):18-24 (1998).There is an average delay of nearly three years from initial symptoms towhen the diagnosis of AD is made (Jorst et al., J. Am. Geriatr. Soc.,43(11):1248-55 (1995)).

It has been recognized that a reliable biomarker would be of significanthelp in the accurate and early diagnosis of AD (Growdon et al.,Neurobiol. Aging, 19:109-116 (1998)). Although several biochemical andgenetic markers are currently available, their clinico-pathologiccorrelations are generally considered too low for routine clinical use.For example, apolipoprotein E ε4 allele is a genetic risk factor whichis found only in 50% of AD cases (Myers et al., Neurology, 46(3):673-7(1996)), and tau and β-amyloid protein measurements in cerebrospinalfluid (CSF) and serum Aβ have significant overlap between AD and non-ADlevels, limiting their usefulness (Pirttila et al., J. Neurol. Sci.,127(1):90-5 (1994); Arai et al., Ann. Neurol., 38:649-652 (1995); Jensenet al., Neurosci. Lett., 186(2-3):189-91 (1995); Motter et al., Ann.Neurol., 38(4):643-8 (1995); Munroe et al., Ann. Clin. Lab. Sci.,25(3):207-17 (1995); Tata et al., J. Neurol. Neurosurg. Psychiatr.,59:280-283 (1995); Vigo-Pelfrey et al., Neurology, 45(4):788-93 (1995);Iwatsubo T., Neurobiol. Aging, 19:161-163 (1998); Nitsch et al., Ann.Neurol., 37(4):512-8 (1995); van Gool et al., Ann. Neurol., 37(2):277-9(1995); Tamaoka et al., J. Neurol. Sci., 151(1-2):65-8 (1996); andPirtilla et al., Arch. Neurol., 53(2): 189-93 (1996)). Other proposedmarkers, such as pupillary response to tropicamide (Scinto et al.,Science, 266:1051-1054 (1994); and Growdon et al., Arch. Neurol.,54(7):841-4 (1997)) and serum factors such as p-97 (Kennard et al., Nat.Med., 2(11):1230-5 (1996)), have not yet been validated in repeatedcontrolled clinical studies. The major drawbacks of most proposed ADmarkers are that they are usually not brain-specific moleculesassociated with AD pathology and that they are not reliably measurablein peripheral fluids.

Neural thread proteins (NTP) are a novel family of recentlycharacterized brain proteins. NTP is a ˜41 kD membrane associatedphosphoprotein with functions related to neuritic sprouting and celldeath (de la Monte et al., J. Clin. Invest., 100:3093-3104 (1997); andde la Monte et al., Alz. Rep., 2:327-332 (1999)). There is compellingevidence linking NTP with AD. NTP mRNA is upregulated in AD braincompared to controls; NTP protein levels in brain and in CSF are higherin AD than controls; and NTP immunoreactivity is clearly found in senileplaques, in neurofibrillary tangles (NFT), in degenerating neurons,neuropil threads, and dystrophic neuritic sprouts in AD and Downsyndrome brains (Ozturk et al., Proc. Natl. Acad. Sci. USA, 86:419-423(1989); de la Monte et al., J. Clin. Invest., 86(3):1004-13 (1990); dela Monte et al., J. Neurol. Sci., 113(2):152-64 (1992); de la Monte etal., Ann. Neurol., 32(6):733-42 (1992); de la Monte et al., J.Neuropathol. Exp. Neurol., 55(10):1038-50 (1996), de la Monte et al., J.Neurol. Sci., 138(1-2):26-35 (1996); de la Monte et al., J. Neurol.Sci., 135(2):118-25 (1996); de la Monte et al., J. Clin. Invest.,100:3093-3104 (1997); and de la Monte et al., Alz. Rep., 2:327-332(1999)). NTP accumulation in neurons occurs early in ADneurodegeneration (before NFT formation). NTP has also been identifiedDown's Syndrome brain tissue (Wands et al., International PatentPublication No. WO 90/06993; de la Monte et al., Alz. Rep., 2:327-332(1999)). Most patients with Down's Syndrome exhibit neuropathologysimilar to that of AD after middle age and develop many cognitivedefects similar to those of AD later in life.

NTP levels in the cerebrospinal fluid (CSF) of AD patients and controlswere shown to be consistently elevated in AD (Chong et al., J. Clin. LabAnal., 6(6):379-83 (1992); de la Monte et al., Ann. Neurol., 32:733-742(1992); de la Monte et al., J. Clin. Invest., 100:3093-3104 (1997);Ghanbari et al., J. Clin. Lab. Anal., 12(4):223-6 (1998); Ghanbari etal., J. Contemp. Neurol., 1998:2-8 (1998); Kahle et al., Neurology,54(7):1498-504 (2000)). Specificity of NTP elevation in AD was shown incomparison to non-AD neurological disease controls, and NTP elevationwas positively correlated with degree of dementia (de la Monte et al.,J. Clin. Invest., 100:3093-3104 (1997); and de la Monte et al., Alz.Rep., 2:327-332 (1999); and Kahle et al., Neurology, 54(7):1498-504(2000)). In one major study, 89% of patients with early AD had NTPlevels of above 2 ng/mL of CSF and 89% of non-AD controls below 2 ng/mLof CSF (de la Monte et al., J. Clin. Invest., 100:3093-3104 (1997)).

Subsequently, the NTP protein was identified in urine by highperformance liquid chromatography, capillary electrophoresis, and ELISA(Ghanbari et al., J. Clin. Lab. Anal., 12(4):285-288 (1998); and de laMonte et al., Alz. Rep., 2:327-332 (1999)). Urinary NTP levels werefound to correlate with CSF levels in AD patients and controls and to besignificantly elevated in AD patients as compared to non-AD patients(Ghanbari et al., J. Clin. Lab. Anal., 12(4):285-288 (1998)). An assayusing gold particles with bound monoclonal anti-NTP in the liquid phasewas developed for urine samples and demonstrated to be both highlysensitive and specific for AD (Fitzpatrick et al., Alzheimer's Reports,3(3):155-159 (2000)).

There is a need to improve upon the existing assays for NTP, including aneed to develop point-of-care assays for NTP which can be conducted in ageneral medical laboratory or a doctor's office. Technical advances suchas methods to routinely purify native NTP from urine in a cost-effectivemanner or the development of easily manufactured analogs to NTP wouldalso improve any such assays

There is evidence showing that NTP may play a direct role in thepathogenesis of AD, thereby making it a target for drug development forthe treatment of AD. NTP is associated with neuritic sprouting; abnormalneuritic sprouting is associated with AD. Over-expression of NTP cancause cellular accumulations of phospho-tau, which in turn precedes theformation of NFT, an important neuroanatomical correlate of dementia inAD (de la Monte et al., Alz. Rep., 2:327-332 (1999)). In addition,over-expression of NTP can cause increased cell death of an apoptoticnature linked to oxidative stress (de la Monte et al., 1999). Inhibitingthe expression or the biochemical action of NTP offers one promisingroute to an effective treatment for AD.

The gene and predicted protein sequence for NTP has been identified anddescribed (de la Monte et al., J. Clin. Invest., 100:3093-3104 (1997)).Neural thread protein was first described and claimed in U.S. Pat. Nos.5,948,634; 5,948,888; and 5,830,670, all for “Neural Thread Protein GeneExpression and Detection of Alzheimer's Disease.”

Other species of neural thread protein (˜26 kD, ˜21 kD, ˜17 kD and ˜15kD) have been identified and associated with neuroectodermal tumors,astrocytomas, and glioblastomas and with injury due to hypoxia,ischemia, or cerebral infarction (de la Monte et al., J. Neuropathol.Exp. Neurol., 55(10):1038-50 (1996), de la Monte et al., J. Neurol.Sci., 138(1-2):26-35 (1996); de la Monte et al., J. Neurol. Sci.,135(2):118-25 (1996); de la Monte et al., J. Clin. Invest.,100:3093-3104 (1997); and de la Monte et al., Alz. Rep., 2:327-332(1999)).

There is a need in the art for improved NTP compositions, useful intherapeutics and diagnostics related to AD and Down's Syndrome, and forcompositions relating to the other species of neural thread proteinuseful in therapeutics and diagnostics for neuroectodermal tumors,astrocytomas, glioblastomas, and other neurodegenerative disorders andfor injury due to hypoxia, ischemia and cerebral infarction. The presentinvention satisfies these needs.

SUMMARY OF THE INVENTION

The present invention is directed to a family of novel repeat sequencesof NTP having the consensus sequence of “H A R L I L (portion of SEQ IDNO: 2, residues 46-51)” and homologs thereof. Harlil peptidesencompassed by the invention include, but are not limited to, “H A R L IL (portion of SEQ ID NO: 2, residues 46-51),” “H A R L C L (portion ofSEQ ID NO: 2, residues 91-96),” “H H A R L C L (portion of SEQ ID NO: 2,residues 90-96),” “H A R L (portion of SEQ ID NO: 2, residues 91-94),”“M F A R L I L (portion of SEQ ID NO: 2, residues 263-269),” “A R L I L(portion of SEQ ID NO: 2, residues 265-269),” “H A R L I F (portion ofSEQ ID NO: 2, residues 292-297),” “H H A R L I F (portion of SEQ ID NO:2, residues 291-297),” and homologs and binding partners thereof. Thisgroup of NTP peptides, and homologous peptides, are collectivelyreferred to as “Harlil peptides.”

The invention arises from the unexpected discovery that the Harlilpeptides have unique binding characteristics:

-   -   they have an affinity to bind to NTP, thereby making them useful        for purification of NTP from bodily fluids, such as urine, CSF,        or blood, as a binding partner for capture of NTP, for the        detection and measurement of NTP in bodily fluids, such as        urine, CSF, or blood, for drug development for AD and Down's        syndrome, as well as other matters disclosed below;    -   they have an affinity to bind to many immunoglobulins, thereby        making them useful for the purification of immunoglobulins, the        detection and measurement of such immunoglobulins;    -   they have an affinity to bind to themselves, thereby making them        useful for the separation, assay measurement, and/or        purification of proteins conjugated to them, the use as an NTP        analog in an assay, as well as other matters disclosed below;        and    -   they appear to function in self-assembly and/or interaction with        NTP with other proteins making them useful as therapeutic        targets.

The invention also encompasses antibodies directed to the Harlil peptidesequences and functional fragments of such antibodies. The antibodiescan be monoclonal or polyclonal antibodies.

Yet another aspect of the invention is directed to binding partners ofthe Harlil sequences on the NTP protein. Such binding partners include,but are not limited to, homologous peptides, organic peptide mimetics,antibodies or portions of antibodies, and paralogues.

The invention encompasses nucleic acids corresponding to the Harlilpeptides, vectors containing at least one nucleic acid encoding at leastone Harlil peptide, and host cells for propagating such vectors, such asE. coli or other useful bacteria or yeast species. The vectors can beused, for example, in therapeutic treatments or in methods of makingHarlil peptides.

This invention further discloses methods of making Harlil peptides,antibodies, and nucleic acids of the invention using conventionaltechniques known in the art.

Another aspect of the invention is directed to pharmaceuticalcompositions comprising one or more Harlil peptides, Harlil peptidemimetics, and/or binding partners thereto, and pharmaceuticalcompositions comprising one or more nucleic acids encoding one or moreHarlil peptides. The pharmaceutical compositions may be useful, forexample, in therapeutic treatments for AD, neuroectodermal tumors,astrocytomas, glioblastomas, and other neurodegenerative disorders.

The invention encompasses the use of a Harlil peptide, correspondingnucleic acid, or Harlil mimetic in diagnostics for AD, neuroectodermaltumors, astrocytomas, glioblastomas, and other neurodegenerativedisorders. Diagnostic tests employing one or more Harlil peptides may beuseful for testing for the presence of antibodies to NTP or to Harlilpeptide sequences, which are indicative of the presence of NTP. WhileNTP is found in all humans, there is an elevated amount found inpatients medically diagnosed as having AD (i.e., DSM4 patients).Alternatively, a diagnostic test can employ one or more antibodies toone or more Harlil peptide sequences, which are useful in detecting thepresence of NTP. The quantity of NTP correlates with the presence of AD,neuroectodermal tumors, astrocytomas, glioblastomas, otherneurodegenerative disorders. Finally, a diagnostic test can employ oneor more nucleic acids encoding one or more Harlil peptides.Hybridization between such nucleic acids and nucleic acids in abiological sample is indicative of the presence of NTP. Again, thequantity of NTP correlates with the presence of AD, neuroectodermaltumors, astrocytomas, glioblastomas, and other neurodegenerativedisorders. The Harlil peptides, Harlil mimetics, antibodies, and nucleicacids of the invention can be labeled in such diagnostic tests.

Yet another aspect of the present invention is directed to diagnostictest kits for implementing a diagnostic method of the invention. Suchtest kits comprise one or more Harlil peptides, Harlil mimetics,antibodies, Harlil binding partners, and/or nucleic acids, and suitablereagents.

The invention also encompasses methods of purifying NTP from solutionsusing a Harlil peptide or Harlil mimetic. Kits for applying such methodsare encompassed by the invention. Such a kit comprises at least oneHarlil peptide, Harlil mimetic, or mixtures thereof and suitablereagents.

Also encompassed by the invention are methods and kits for purifyingantibodies using a Harlil peptide of the invention. Such a kit comprisesa Harlil peptide of the invention and suitable reagents.

The present invention is further directed to a method of treatment forAD, neuroectodermal tumors, astrocytomas, glioblastomas, or otherneurodegenerative disorder comprising administering to a mammal in needa therapeutically effective amount of one or more Harlil peptides,Harlil mimetics (not limited to Harlil peptide mimetics), antibodies,and/or nucleic acids of the invention.

Both the foregoing general description and the following detaileddescription are exemplary and explanatory and are intended to providefurther explanation of the invention as claimed. Other objects,advantages, and novel features will be readily apparent to those skilledin the art from the following detailed description of the invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: Shows the complete NTP sequence and the location of the Harlilsequences within the complete NTP sequence (de la Monte et al., J.Neuropathol. Exp. Neurol., 55:1038-1050 (1996));

FIG. 2: Shows the inhibition of rabbit anti-mouse immunoglobulinconjugate binding to a Harlil peptide (NTP-3) coated microtiter plate asa function of competing NTP-3/RGG concentration (x axis) (data describedin Example 5);

FIG. 3: Shows the results of assays of 107 biological samples using aHarlil peptide based membrane assay (data shown in Example 4);

FIG. 4: Shows the results of an assay which determines the portion of anantibody to which NTP binds (data shown in Example 6);

FIG. 5: Compares the linearity of a urine control sample and recombinantNTP in an ELISA format competitive NTP assay (data shown in Example 8);

FIG. 6: Shows the results of a competitive affinity assay to distinguishAD diagnosed samples for age-matched normals in an ELISA format using aHarlil peptide, which demonstrates a threshold amount present inAD-positive patients (data described in Example 8).

DETAILED DESCRIPTION OF THE INVENTION

(a) 45-51 T H A R L I L (portion of SEQ ID NO: 2) (b) 90-96 H H A R L CL (portion of SEQ ID NO: 2) (c) 263-269 M F A R L I L (portion of SEQ IDNO: 2) (d) 292-296 H H A R L I F (portion of SEQ ID NO: 2)

See FIG. 1.

The invention encompasses peptides having the sequence of any of regions(a), (b), (c), (d), or homologs of these (including but not limited to“H A R L M L”) (SEQ ID NO: 3). The Harlil peptides can also haveadditional amino acid residues before or after the Harlil sequence onlinker peptides. The additional amino acid residues or linker peptidesmay be those found in the NTP sequence before and after the Harlilsequence. For example, the amino acid residues G I T G M C T (portion ofSEQ ID NO: 2, residues 39-45) occur before residue 46 and the amino acidresidues Y F F L V (portion of SEQ ID NO: 2, residues 52-56) occur afteramino acid 50 in the NTP sequence. Thus, a Harlil peptide encompassed bythe invention includes the NTP peptide G I T G M C T H A R L I L Y F F LV (portion of SEQ ID NO: 2, residues 50-56). For the Harlil peptidesrecited in (b), (c), and (d), the additional amino acid residues arethose that flank the Harlil sequence in the NTP sequence. However, thereis no evidence that the flanking sequences serve as other than a linker.Preferably, the Harlil peptide having additional amino acid residuesdoes not exceed 25 total amino acid residues in length.

Homologs and variants of the Harlil peptides are also encompassed by thescope of the invention. It is common to vary peptide sequences bysubstituting one amino acid for another. Depending on the purpose forwhich the amino acid is being varied, the amino acid can be replacedwith a similar or homologous amino acid or a dissimilar amino acid.There are many scales on which amino acids can be ranked as similar orhomologous. (Gunnar von Heijne, Sequence Analysis in Molecular Biology,p. 123-39 (Academic Press, New York, N.Y. 1987).

The Harlil repeat sequence has the following unique characteristics: (1)it can bind to NTP; (2) it can bind to many immunoglobulins; and (3) itcan bind to itself. These unique characteristics enable and suggestvarious diagnostic and therapeutic applications, as described below.

A. Compositions

The present invention is directed to Harlil peptides of NTP, the use ofsuch peptides, peptide mimetics, binding partners, and/or homologs asaffinity binding partners of NTP for assay or purification of NTP, theuse of Harlil peptides, peptide mimetics, and homologs thereof to blockthe Harlil peptide sites on NTP, or the use of substances that interactwith NTP through the Harlil sequences. Also encompassed by the inventionare antibodies directed to such Harlil peptide sequences, and nucleicacids corresponding to the Harlil peptides and homologs thereof.

Harlil peptides and homologs thereof can be made using conventionalpeptide synthesis techniques. Mimetics of Harlil peptides can bedeveloped using combinatorial chemistry techniques.

Monoclonal antibodies to a Harlil peptide sequence can be made, forexample, by the hybridoma method first described by Kohler & Milstein,Nature, 256:495 (1975), or by recombinant DNA methods (see e.g., U.S.Pat. No. 4,816,567). Polyclonal antibodies (i.e., antisera), can bemade, for example, by immunizing host animals such as rabbits or sheep,with a Harlil peptide as an immunogen. The immunization typicallyinvolves repeated inoculations with the immunogen, typically at leasttwo at about one week intervals. Such inoculation raises an immuneresponse against the immunogen and causes the inoculated host's immunesystem to produce antibodies against the immunogen. Serum from theimmunized host will usually be collected about three to ten days afterthe final booster. Immunoglobulins may be separated from the serum byammonium sulfate precipitation, gel electrophoresis, dialysis,chromatography, or other conventional separation and purificationtechniques.

Nucleic acids corresponding to Harlil peptides can be made, for example,using (a) standard recombinant methods, (b) synthetic techniques, or (c)combinations thereof.

B. Properties of the Harlil Peptides

1. Binding to NTP

The Harlil sequence shows binding specificity to NTP. When a Harlilpeptide, or an analogue thereof, is immobilized it can be used to purifyNTP from solutions. When it is used to capture NTP as part of anaffinity assay, the binding to NTP is very specific and is unaffected bypH from 3.5 through pH 8. The sensitivity of this affinity assay is atleast as high as an immunoassay. For example, a positive urine poolwhich contains about 0.5 ng/mL NTP by ELISA can be diluted almost 4 foldand still be differentiated from a negative pool by this affinity assay(this is described in more detail in Example 6, below). Moreover, assaysensitivity can be improved by using a more sensitive detection means,such as by using fluorescent or chemiluminescent substrates orradio-labeled assays.

Because the Harlil peptides of the invention bind specifically to NTP,they can be used in diagnostic assays for detecting the presence of NTPor antibodies to NTP in a biological sample. Above normal levels of NTPin bodily fluids have been shown to indicate the presence of AD, Down'sSyndrome, or other degenerative brain disease.

2. Binding to Immunoglobulins

Harlil peptides bind to many immunoglobulins. The peptide bindingappears to be via the Fc portion of the antibody, and not via the Fabportion. The binding to immunoglobulins occurs at physiological pH,though some immunoglobulins also bind at lower pH's. Binding at a lowerpH indicates the strong affinity between the Harlil peptide and certainantibodies, and eliminates the possibility that the binding was due tocharge/charge interactions rather than affinity.

Because Harlil peptides bind to immunoglobulins, they are useful in thepurification of immunoglobulin molecules. The Harlil monomer affinityfor immunoglobulin is quite low and thus, the avidity of Harlilconjugates can be controlled by controlling peptide density. Withincreased Harlil peptide density, the affinity for immunoglobulinincreases. It is desirable to use low to moderate affinity columnsbecause high affinity columns require harsh elution conditions, whichcan denature proteins and antibodies, and elute in broad dilute peaks,which is undesirable because of dilution of eluted products (Wikström etal., J. of Chromatography, 597:83-92 (1992)). Such dilution requiresfurther concentration of the eluted proteins or antibodies, and resultsin loss and/or damage of protein or antibody product.

In contrast, low affinity chromatography, such as that which can be usedwith a Harlil peptide, has the advantage of sharpening the elution peakand avoiding harsh conditions. Ibid. Such purification procedures arevaluable for purifying therapeutic and diagnostic antibodies byproviding purified proteins useful in pharmaceutical and diagnosticapplications.

Prior known peptide analogs useful for immunoglobulin purification havemuch longer sequences than that of a Harlil peptide and appear torequire or mimic a secondary structure through which they interact withimmunoglobulins (Fassina et al., J. is of Mol. Recognition, 9:564-569(1996); Guerrier et al., J. of Mol. Recognition, 11:107-109 (1998);Palombo et al., J. of Mol. Recognition, 11:247-249 (1998); Braisted etal., Proc. Natl. Acad. Sci. USA, 93:5688-5692 (1996); Fassina et al., J.of Mol. Recognition, 11:128-133 (1998); Palombo et al., J. of Mol.Recognition, 11:243-246 (1998); Li et al., Nat. Biotechnol., 16:190-195(1998); and U.S. Pat. Nos. 5,084,559; 5,100,788; 6,013,763. Therelatively short Harlil peptides of the invention are much easier andcost effective to produce and store.

Yet another application of the Harlil peptides of the invention relatesto their use in diagnostic tests in formats such as ELISA andimmunochromatography strips. Because the Harlil peptides of theinvention bind to immunoglobulins, the peptides provide a cost-effectivetrap material substitute for anti-antibody and Proteins A and G forcapture, separation, or anchorage in immunoassay systems. The currenttrap materials employed in ELISA and immunochromatography strips, i.e.,anti-antibody and Proteins A and G, are expensive to make and maintain.This is in contrast to the relatively simple to make and cost-effectiveto store Harlil peptides of the invention.

3. Binding to Itself

The Harlil peptides and analogues of the invention are capable ofbinding to themselves, and thus when conjugated to proteins, theproteins will self-aggregate if they are not maintained at a very low pHor at very low dilution. The carrier protein may self-aggregate andprecipitate out of solution at neutral pH.

In addition, because of its unique self-binding characteristic, a Harlilpeptide can be used as an NTP analog in an assay. This is because theHarlil peptides duplicate the self-binding characteristic of NTP. In asequential or competitive assay, NTP will bind to the Harlil peptideconjugate solid phase, and remain on during washes where it blocks thebinding of immunoglobulin (such as rabbit IgG). The Harlil peptides canalso be used as a capture antibody replacement in a sandwich assay. TheHarlil peptides of the invention are less expensive and more costeffective assay materials than the NTP protein.

The self-aggregation property of Harlil peptides may have therapeuticapplications. Because Harlil sequences cause proteins to which they areconjugated to bind to one another, this indicates that through thesesequences NTP self-associates and/or associates with other proteins.This association could be intramolecular or intermolecular. The abilityof an affinity column and a microtiter plate to bind free NTP (asdescribed in the examples, below) indicates that in native NTP theHarlil sequence is probably surface accessible.

It is possible that the toxicity of NTP is in whole or part due to thehighly interactive Harlil sequences. Thus, toxicity of NTP could be dueto self-aggregation or it could be due to interaction of the highlyreactive Harlil sequences with other cerebral components. By blockingthis sequence of NTP, one may block its interactive capability.

It is clear that NTP participates in the neurodegenerative cascade. Theability to interrupt or redirect the cascade by targeting NTP offers atherapeutic opportunity. For example, it may be possible to intervenetherapeutically by using the ability of the Harlil peptides to interactwith NTP binding sites, thus blocking potential reactive sites on NTP.Alternatively, the Harlil peptides and mimetics of the invention may beuseful to target drugs to cells expressing the Harlil sequence.

Peptides that self associate have been used in biomaterials asbioadhesives. Thus one can use the self associative or self recognitionqualities of the peptide to induce non-associative proteins or peptidesto associate, to anchor moities to surfaces, or to direct molecules totargeted sites. It is recognized that such cell adhesion inducingpeptides could be useful in the design of synthetic tissues and organs(Mayo, K. H., TIBTECH, 18:212-217 (May, 2000). Such materials have alsoshown themselves useful in construction of gel systems that are pH andbinding sensitive (Id.). In addition, polymerization and/or multiplerepeats of Harlil peptide sequences could provide compositions havingstructural features and higher avidity.

The repetition of the Harlil sequence in the NTP sequence indicates thatthe Harlil sequence probably plays a role in the assembly orpolymerization of NTP. For example, in collagen the regions of theseparate strands that self associate at sites that subsequently formpyridinoline linkages also exhibit high homology, indicating that theseself-identifying homologous regions serve a key structural andfunctional purpose. It is likely that the “HARLIL” sites individually orin polymer array interact with other brain proteins and are key to thefunctionality of NTP.

If NTP overproduction contributes to AD and related diseaseneurodegenerative disease pathology, then the production or folding ofthe NTP protein might be inhibited, and/or the polymerization or theinteraction of NTP with other components might be prevented, withtherapeutics based on the HARLIL (portion of SEQ ID NO: 2, residues46-51) model. For example, if by administration of one or more Harlilpeptide or Harlil mimetics, NTP aggregation, or folding or assembly,could be inhibited, one might expect enhanced protease degradation ofNTP: Thus one might accomplish removal of excess NTP by administrationof one or more Harlil peptide or Harlil mimetics. Alternately a Harlilpeptide or Harlil mimetic therapeutic may be useful to control theinteraction of NTP monomer or aggregate with other components of theneurodegenerative cascade.

Numerous proteins that self assemble or polymerize have repeatstructures. The best known is collagen that bears the short repeatsequence gly X Y as many a six times per chain. (Lacy et al.,“Identification of FLRT1, FLRT2 and FLRT3: a novel family oftransmembrane leucine rich repeat proteins,” Genomics, 62(3):417-26(1999).) Other studies have shown that specific repeating sequences areinvolved in nucleation of binding. (Snellman et al., “A short sequencein the N-terminal region is required for the trimerization of type XIIIcollagen and is conserved in other collagenous transmembrane proteins,”EMBO J., 19(19):5051-59 (2000).) Further there are studies showing thatthe collagen peptide Pro Pro Gly, which is critical to self assembly, isalso critical in the interaction of procollagen with the chaperone HSP7.(Koide et al., Conformational requirements of collagenous peptides forrecognition by the chaperone protein HSP47,” Biol. Chem.,275(36):27957-27963 (2000).) The specificity of self recognition inlaminin has been studied. (Schittny, J. C., “Affinity RetardationChromatography: Charaterization of the Method and Its Application,”,Anal. Biochem., 222:140-148 (1994).)

Thus, it is evident that proteins that polymerize or form fibrilarstructures do so generally by self assembly through specific domains onthe protein recognizing specific domains on self (self-recognition).Further, these proteins may use these same recognition sites forinteractions with other proteins. As with Protein A interactions with Fc(Deisenhofer, J., “Crystallographic Refinement and Atomic Models of aHuman Fc Fragment and Its complex with Fragment B of Protein A fromStaphylococcus aureus at 2.9- and 2.8-A Resolution,” Biochem.,20(9):2361-2370 (1981)), these interactions like that of the Harlilsequence appear to be through hydrophobic and ionic interactions.

In the case of NTP it appears that the Harlil domains, which functionmost probably in self assembly, are highly homologous and, indeed,almost completely conserved. The “leucine zipper” uses self-recognitionin which leucine rich stretches bind together. A leucine zipper is,however, not as unique as the Harlil sequence. The Harlil sequence isenvisaged to play a critical role in self assembly and the interactionof NTP with other brain components.

Prions and experiments with prion elements. in yeast provide evidencethat proteins can assume a self aggregating conformation. (Serio et al.,“Nucleated Conformational Conversion and the Replication ofConformational Information by a Prion Determinant,” Science, 289:1317-21 (2000); and Sparrer H. E., “Evidence for the Prion HypothesisInduction of the Yeast (PSI+) Factor by in vitro-Converted Sup35protein,” Science, 289(5479):595-599 (2000).)

Li and Lindquist have shown that they can confer the SUP prion activityon an unrelated protein by genetically fusing portions of the SUPprotein containing the peptide sequence 22-69. Thus, they demonstratedthat the prion conferring characteristic of the SUP35 protein resides inthe SUP 22-69 peptide. In analogy, the present invention is directed toa self-identifying peptide that causes aggregation. By grafting thesequence onto a protein (by conjugation) self aggregation can beconferred onto that protein: as a result, immediate precipitation of upto 95% of the Harlil protein conjugate at physiological pH is observed.

The following examples are given to illustrate the present invention. Itshould be understood, however, that the invention is not to be limitedto the specific conditions or details described in these examples.Throughout the specification, any and all references to a publiclyavailable document, including a U.S. patent, are specificallyincorporated by reference.

Example 1

The purpose of this example was to identify several Harlil sequences ofneural thread protein and determine their reactivity with NTP.

The following Harlil sequences were synthesized (Synpep, Dublin Calif.)and conjugated to maleimide activated Rabbit IgG (JacksonImmunoresearch, West Grove Pa.) and assessed for their NTPimmunoreactivity. A linker was added, which is a repetition of theprotein sequence occurring before and after the 90-96H H A R L C L(portion of SEQ ID NO: 2) sequence of NTP. (SEQ ID NOS 4-11,respectively, in order of appearance)

1. (NTP-1)                   L H A R L C L A N F C G R N R V 2. (NTP-2)                    L A R L C L A N F C G N N N V 3. (NTP-3)     C A R YR T G H H A R L M 4. (NTP-4)                   H H A R L P L A N F C G5. (NTP-5)             R T G H H A R L C*L A N F C 6. (NTP-6) C E S A RY R T G H H A R L C * 7. (NTP-7)             D N T H H A R L I L 8.(NTP-8)                 S H H A R L I L *Blocked with Acetamido Methyl(C₃H₆NO).

Conjugation to carrier proteins was through a cysteine. Thus, peptidesNTP-1 and NTP-2 produced mixed conjugate results because there is morethan one cysteine residue. Therefore, for peptides NTP-5 and NTP-6, thesecondary cysteine was blocked with ACM.

The location of the identified sequences in the NTP sequence is shown inFIG. 1. While all of the Harlil analogs showed some reactivity, NTP-3was selected for most of the studies because it provided good reactivitywhile being easier to work with as it had a single cysteine residue.

As mentioned above, homologs and variants of the Harlil peptides arealso encompassed by the scope of the invention. For construction of thehomologous peptides of this example, homologous amino acids were used.The substitution criteria used were charge and/or size. Thus, the choiceto substitute methionine for cysteine in NTP peptide 3 was based onoverall similarity between these two amino acids and the desire toremove a reactive cysteine from this critical stretch of amino acids.The choice to substitute proline for cysteine was an attempt to see ifthis would mimic the conformational form of the peptide when it was inthe protein and the cysteine was in disulfide linkage.

Other changes known to persons of skill in the art to affect or studyaffinity interactions include, but are not limited to, for example,interchanging leucine with other hydrophobic amino acids, such asisoleucine, valine, alanine or glycine; interchanging acidic amino acidsor basic amino acids; interchanging histidine with phenylalanine todetermine the effect of charge vs spatial; interchanging asparagine withaspartic, or glutamine with glutamic, to evaluate the effect of chargevs spatial; and interchanging serine with threonine, threonine withcysteine, aspartic with glutamic, arginine with lysine or histidine, andtyrosine with tryptophan or phenylalanine.

There appears to be no reason that the flanking sequences of NTP arerequired except as spacers, as only the Harlil peptide sequence hasactivity. The changes introduced to the flanking sequences were done torender the peptide less basic or hydrophobic.

Example 2

The purpose of this example was to demonstrate the use of NTP-3 as anaffinity ligand for affinity purification of NTP. In this process, NTPwas purified on affinity column from a urine sample obtained from an ADpatient.

Preparation of the urine sample containing NTP for Testing: theBiological Source of NTP used was the urine of a patient (BOUL)diagnosed with AD. Before application to the column material, thebiological sample was processed according to the following protocol forprocessing of urine for AD testing:

-   -   1. The urine was tested with an Ames Multistix™ (Bayer, Ind.).        Samples are discarded if they: (a) are positive for bacterial        contamination; (b) positive for pathologically high levels of        protein, such as those associated with kidney disease (this test        does not exclude samples positive for NTP lacking pathological        levels of proteins), ketones, blood, urobilogen, nitrite,        leucocytes; (c) have a pH greater than 7.5 or less than 4.5;        or (d) have a specific gravity greater than 1.025.    -   2. The urine was centrifuged at 3000×g for 15 minutes to remove        cellular debris.    -   3. The urine was filtered using a syringe through a 0.22 μm        cellulose acetate filter, and the filtrate was brought to 0.05%        azide.    -   4. The resultant aliquot was placed in the top reservoir of an        Amicon Centricon® YM-10 Millipore, and centrifuged at 3000×g for        one hour.    -   5. The sample, which was now about 25% of the original volume,        was removed from the centrifuge and restored to the original        volume with 1.5 mL of Tris Buffered Saline (TBS).    -   6. Steps 4 and 5 were repeated, in which the sample was        centrifuged again at 3000×g for thirty minutes, followed by        removal of the sample from the centrifuge, and 1.5 mL of TBS        were added to the sample.    -   7. The sample was then centrifuged at 3000×g for thirty minutes,        followed by removal of the sample from the centrifuge. The        sample was then one fourth of the original volume.    -   8. The sample was then transferred to a borosilicate glass vial        and stored frozen at −20° C.        Preparation of the column: NTP-3 was conjugated to cyanogen        bromide-activated agarose (Sigma, St. Louis, Mo.) according to        the manufacturer's directions. Once prepared, the column        material was stored in 25 mM TRIS buffered saline (TBS), pH 7,        with 0.01% azide.        Chromatography: 11 mL of the affinity column material was        incubated for one hour with 25 mL of the urine sample (processed        as described above to obtain a four times concentrated sample in        TBS (pH 7)) and 25 mL of 0.025 M glycine buffer (pH 3.5). The        unabsorbed material (pass through) was collected. The column was        then washed with 5 volumes of 1×TBS (pH 7) and eluted in 11 mL        of 0.1 M glycine (pH 2). Immediately following elution, the        eluate was adjusted to pH 7 with NaOH, followed by concentration        to 1 mL using an Amicon Centricon® YM-10 (Millipore, Beverly        Mass.) as in Example 1.        Analysis of NTP Activity Present in the Affinity Column Eluate:        Affinity assay activity was assayed using 7C Gold™ Strips, which        test for neuronal thread protein in urine (Nymox Pharmaceutical        Corp., Maywood N.J. See e.g., Fitzpatrick et al., Alzheimer's        Reports, 3(3):155-159 (2000)). All activity as assayed by the 7C        Gold™ strip was in the pH 2 eluate fraction.        Protein Concentration The protein concentration in the eluate        was 108 μg, as determined by Coomassie Blue staining (BioRad,        Hercules, Calif.). This is about 3% of the starting protein        concentration. Protein concentration was 145 μg, as determined        by Bicinchoninic Acid Kit (Cat. # 23223, BioRad). Absorbance        corrected for the buffer at 280 nm was 390, indicating 390 μg of        protein. The larger protein amount obtained with absorbance        measurement is likely a result of the presence of a large amount        of aromatic amino acids in NTP, which can cause overestimation        of protein using this measurement technique.        Analysis of the NTP Protein From the Affinity Column Eluate by        Gel Electrophoresis: 1 μg of the eluate (approximately 110-145        ng) was run on a 12.5% sodium dodecyl sulfate (SDS) mini-gel        (Amersham Pharmacia Biotech, Sweden) and stained with silver.        Bands were observed at about 29 kD, 33 kD, 40-45 kD, and 60 kD.        The gel was sliced into bands at 20-35 kD, 35-45 kD, and 45-65        kD and placed in 100 μl of TBS, and allowed to dialyze against        the TBS overnight. The band eluates were then concentrated using        an Amicon Centricon® YM-10, as in Example 1, and assayed for        activity using the 7C Gold™ Assay.

NTP reactivity was observed in the 35-45 kD band, at about 41 kD. Noactivity was observed for the other bands. NTP has a reported molecularweight of 41 kD. Thus, the data indicate that the NTP-3 bound to theaffinity column selectively bound the NTP protein present in the urinesample of the AD patient.

This example demonstrates the specific binding of the Harlil peptideNTP-3 to NTP, and the use of a Harlil peptide, such as NTP-3, as anaffinity ligand for affinity purification of NTP.

Example 3

The purpose of this example was to show the self-aggregation ability ofa Harlil peptide. The Harlil peptide NTP-3 forms disulfide bonds(because of the cysteine residue) and dimerizes at neutral pH. Since thedimerized peptide can bind two immunoglobulins, it can causeprecipitation. This property of Harlil peptides was demonstrated usingrabbit immunoglobulin.

1 mg of the Harlil peptide NTP-3 in 1 mL of dimethylsulfoxide (DMSO) wasadded to 3.4 mg of rabbit IgG (Jackson Immunoresearch, West Grove, Pa.)at pH 7. The mixture was allowed to dialyze over night, and a clearwhite precipitate was observed the next morning. The precipitate wasremoved by centrifugation and the protein concentration of thesupernatant was determined by absorbance at 280 nm using a Perkin Elmerspectrophotometer model Lambda 3B. The results are shown in Table 1.Precipitation of immunoglobulin is prevented at a low pH, e.g., pH of3.5 or less 3.5.

TABLE 1 Immunoglobulin Precipitated Using a Harlil Peptide StartingConcentration Final Concentration % Protein Precipitated 3.4 mg RGG* +2.7 mg 39% 1 mg NTP-3 *rabbit IgG

This example demonstrates the ability of Harlil peptides to be used toisolate and/or purify immunoglobulins.

Example 4

This example illustrates the usefulness of Harlil peptides in detectingand quantitating the presence of NTP.

Membrane Based Assay: The 7C Gold™ assay consists of a 5 mm×45 mm strip,with two traps and a sample receiving zone located on the strip. Traps 1and 2 are located 16 and 24 mm distal from the sample receiving zone,respectively. Each trap is about 4 cm deep.

The labeled gold particles migrate to trap 1 or 2. The ratio of labeledgold in traps 1 and 2 correlates with the amount of NTP present in thesample. See U.S. Pat. No. 6,121,008 to Fitzpatrick et al.Preparation of NTP-3 Conjugate: Malemide activated rabbit immunoglobulin(RGG) (Pierce, Rockford, Ill.)) at a concentration of 3.8 mg/mL wasbrought to a pH of 3.5 using 1 M citrate. The Harlil peptide NTP-3, inDMSO at a 30 fold molar excess, was then added to the RGG. The NTP-3/RGGconjugate was monitored for pH and allowed to react overnight at roomtemperature with slow stirring. The conjugate was then thoroughlydialyzed against 0.5 mM, pH 3.5, citrate phosphate buffer.Preparation of 7C Gold™ Strip Assay: The dialyzed NTP-3 conjugated toRGG was diluted to 1 mg/mL in 0.5 mM, pH 3.5, citrate phosphate buffer.After standing overnight, 6 μl/cm of the conjugate was coated on amembrane (Loprodyne 3, Pall, East Hills, N.Y.) using a XY3000™ Biodot(Irvine, Calif.) at Trap 1. Next, 0.5 mg/mL of goat anti-mouseimmunoglobulin (DAKO #20109, Denmark) was coated on the membrane onecentimeter above the NTP-3/RGG conjugate at Trap 2 (using the sameparameters as the NTP-3/RGG coating). The membrane, or 7C Gold™ Strip,was hot aired dried for 30 minutes, cut into 5 mm strips, and storedwith desiccant. This trap will bind anti-NTP-antibody coated gold in theabsence of NTP. The 7C Gold™ assay uses an anti-NTP antibody N314 (de laMonte et al., J. of Neuropath. Exp. Neurol., 55:1038-1050 (1996)). Thebasis of this assay is that NTP is sequestered by the N3I4 anti-NTPantibody on gold and transported to the NTP-3 trap, where the NTP iscompeted off the N3I4 and binds to Trap 1. In doing so, the NTP blocksthe binding of the antibody on the gold to trap 1 and, as a result, thegold migrates to Trap 2. Thus, in the presence of NTP more gold migratesto Trap 2.Colloidal Gold: Colloidal gold was prepared as described in ColloidalGold, M. A. Hayat ed. (Academic Press Limited, London (1991)), andcoated with purified N3I4 anti-NTP antibody at a concentration of 20μg/mL. The antibody-coated colloidal gold was then diluted intocryopreservative buffer (Serex Inc., Maywood, N.J.) and freeze dried. Anamount sufficient for one strip was freeze dried in a 2 mL borosilicatevial (Wheaton #223683; Millville, N.J.) using a Virtus (Gardiner, N.Y.)Model 600SL & 12 SL freeze drier.Patient Samples: 107 patient samples were processed and concentrated, asdescribed in Example 2.The 7C Gold™ Assay: 50 μl of each processed and concentrated patientsample was added to the NTP-antibody coated freeze dried gold. Themixture was incubated for 15 minutes at room temperature, followingwhich the 7C Gold™ strip was placed in the vial until completion of theassay, as indicated by the appearance of a green line at the top of thestrip. The strip was removed and allowed to dry.Summary of Results: In the absence of NTP, most of the NTPantibody-coated gold binds to the Harlil peptide NTP-3 trap. The NTPHarlil peptide solid phase microtiter plate binds mouse antibody withvery low affinity, but in its aggregated state on gold the N3I4monoclonal antibody binds to the trap. The intensity of the color inbands one and two were then read using a densitometer (Gretag D19C,Switzerland). The Ratio Value, which is equal to Trap 1 reflectancedivided by the reflectance in Trap 1 plus the reflectance in Trap 2, wascalculated and the Ratio Value of the sample was divided by the ratiovalue of an index or cutoff sample. This value was designated theindexed value. The results of the assay, graphed in FIG. 3, showexcellent separation of normal samples from AD samples.

Example 5

The purpose of this example was to show that binding of NTP to a Harlilpeptide coated microtiter plate could be inhibited by unconjugatedHarlil peptide.

Preparation of Microtiter Plate: The Harlil peptide/immunoglobulincomplex NTP3-RGG, in a ratio of 30:1 and prepared as in Example 4, wascoated on an Immulon 4 microtiter plate (Dynex, Chantilly, Va.) at aconcentration of 0.5 μg/well.Standards: Recombinant NTP in TBS (described in de la Monte et al., J.of Neuropath. Exp. Neurol., 55:1038-1050 (1996)). 0.01% azide (NymoxPharm. Corp., Lot 4-7-98), was serially diluted into TBS. 100 μl of eachdilution was incubated at pH 3.5 for one hour. The dilutions were thenwashed for fifteen minutes in TBS, 0.1% albumin, and 0.05% Tween 80.This was followed by 3 washes in TBS and 0.05% Tween 80.Microtiter Plate Assay: 100 μl of 1:8000 dilution of peroxidaseconjugated rabbit IgG (Jackson Immunoresearch, West Grove, Pa.) was thenadded and allowed to react for 30 minutes. The microtiter plate waswashed twice with TBS and 0.05% Tween 80, followed by the addition of150 μl of tetramethylbenzene (TMB) (Serex Inc., Maywood, N.J.). Themixture was then incubated for 10 min. and stopped with 50 μl of 2 NHCl. Absorbance was read in a SLT 340 ATTC spectrophotometer.

Using this system, it is shown that monomer NTP-3 inhibits the bindingof conjugate to the plate. See FIG. 2.

Example 6

The purpose of this example was to demonstrate that antibodiesspecifically bind to a Harlil peptide coated microtiter plate and totest what portion of the antibody (Fc or Fab) is binding to the Harlilcoated plate.

Antibodies Tested: The following antibodies were obtained from JacksonImmunoresearch (West Grove, Pa.): (1) alkaline phosphate (AP) labeledaffinity purified rabbit IgG anti-mouse antibody; (2) AP labeledaffinity purified rabbit IgG anti-mouse (Fab2); and (3) AP labeledaffinity purified rabbit IgG anti-chicken.

Rabbit IgG anti-chicken (antibody (3)) was used to eliminate thepossibility that the rabbit anti-mouse (antibody (2)) was recognizingthe RGG in the NTP-3/RGG conjugate. Antibody (2) was identical toAntibody (1), except that Antibody (2) lacked the Fc portion of the IgG.

The assay format was as in Example 5. Non-immune purified rabbit,chicken, and mouse IgG was added up to 1 mg/mL (see FIG. 4). Controlswere 1 mg/mL BSA (bovine serum albumin), alpha-glycoprotein, AD positiveand negative control urine, and 80, 40, 20, 10, and 5 units ofRecombinant NTP. Both rabbit and chicken IgG competed off the APconjugate in a dose-dependent manner. See FIG. 4. Fab2 did not bind tothe plate.

Summary of Results: Both whole molecules, the rabbit anti-mouse and therabbit anti-chicken, bound to a microtiter plate coated withNTP-3/rabbit IgG. The Fab labeled antibody did not exhibit any binding(results not shown). These results indicate that Harlil peptide antibodybinding is effected through recognition of the antibody Fc region.

The affinity of Harlil peptides for IgG of different species varies. Forexample, mouse monoclonal antibody exhibited much lower affinity for theNTP-3 conjugates than did rabbit IgG. See FIG. 4.

Example 7

The purpose of this example was to determine whether NTP recognizes thesequence in Protein G which recognizes the Fc portion of antibody.

Protein G binds antibody through the Fc region. Since the results ofthis example suggest that Harlil peptides also bind the Fc portion ofimmunoglobulins, and not the Fab portion, it was determined whether NTPrecognizes the sequence in Protein G which recognizes the Fc portion ofantibody. Specifically, since Harlil peptides recognize Harlil peptides,Harlil peptides recognize the Fc region of antibody, and Protein Grecognizes the Fc region of antibody, this experiment determined whetherProtein G recognizes NTP.

Both an NTP positive and an NTP negative sample were passed through aProtein G column. NTP was not significantly reduced. These resultssupport the conclusion that Protein G does not bind to NTP.

Binding through the Fc region may have therapeutic implications, as theFc region is used to recognize receptors in the immune system.

Example 8

The purpose of this example was to demonstrate a competitive affinityassay in a microtiter plate assay format using a Harlil peptide.

Preparation of the Microtiter Plate. The Harlil peptide/immunoglobulincomplex NTP-3/RGG, in a ratio of 30:1 and as prepared as in Example 4,was coated on an Immulon II microtiter plate (Dynex, Chantilly, Va.) ata concentration of 20 μg/well.Preparation of Samples: Thirty Urine Samples were Prepared for Testingas Described in Example 2. The filtrate was tested after the sample wasspun in a 100 K Amicon Centricon (Millipore Inc., Beverly Mass.) toremove any antibody, as antibody Fc could interfere in the assay. (Toprevent false positives in diagnostic tests, the ability of a Harlilpeptide to bind non-NTP antibodies is disabled. For example, sampleshaving immunoglobulin levels greater than 100 μg/mL must haveimmunoglobulin levels reduced to less than 100 μg/mL prior to assay.)Controls: A urine pool prepared from urine of individuals with nodiagnosis of any neurodegenerative diseases was passed over an affinitycolumn, prepared as described in Example 2. The resultant urine pool isreferred to as “stripped” urine.

Stripped urine was then used to prepare a mid range control byappropriate dilution of a high pool. The high pool was prepared from acollection of samples from patients diagnosed with AD who testedpositive in the assay for NTP (see Example 4).

Standards. Recombinant NTP (Nymox Pharmaceutical Corp, Montreal Canada)was diluted into TBS to form standards. Standards were assigned unitvalues of 40, 20, 10, and 0. Because there is evidence that NTP in urinemay be partially degraded, the amount of NTP was expressed inRecombinant NTP units and not in weight. FIG. 5 compares the linearityof a urine control sample and recombinant NTP in a microtiter formatcompetitive NTP assay.The Assay. Patient samples were tested in the assay as follows: 50 μL ofa 1:5000 dilution of peroxidase conjugated rabbit IgG (JacksonImmunoresearch, West Grove, Pa.) and 50 μl of sample or standard wasadded to the wells of the plate. The plate was incubated at 1 hour atroom temperature, and then washed three times in TBS, 0.1% albumin, and0.05% Tween 80. 100 μl of PNPP (Para Nitro Phenyl Phosphate) (Moss,Pasadena, Md.) was added to each well. The OD at 405 nm was read on aBioRad Reader at 30 minutes and thereafter at fifteen minute intervalsuntil the OD of TBS standard was between 2-2.5. The results, shown inFIG. 6, demonstrate that while NTP is found in all samples, there is anelevated amount present in AD-positive patients. This elevated amountcan easily be determined using age-matched controls. Thus, a diagnostictest which determines the amount of NTP in a biological sample can beuseful in the diagnosis of AD or other neurodegenerative disorder withhigh accuracy.

It will be apparent to those skilled in the art that variousmodifications and variations can be made in the methods and compositionsof the present invention without departing from the spirit or scope ofthe invention. Thus, it is intended that the present invention cover themodifications and variations of this invention provided they come withinthe scope of the appended claims and their equivalents.

1. A nucleic acid encoding an amino acid sequence selected from thegroup consisting of: (a) H H A R L; (portion of SEQ ID NO: 2, residues291-295) (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295) (c) HA R L I; (portion of SEQ ID NO: 2, residues 292-296) (d) H A R L I L;(portion of SEQ ID NO: 2, residues 46-51) (e) H H A R L C L; (portion ofSEQ ID NO: 2, residues 90-96) (f) A R L I L; (portion of SEQ ID NO: 2,residues 47-51) (g) H H A R L I F; (portion of SEQ ID NO: 2, residues291-297) (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51)(i) A R L I; (portion of SEQ ID NO: 2, residues 47-50) (j) A R L; (k) HA R L C L; (portion of SEQ ID NO: 2, residues 91-96) (l) A R L C L;(portion of SEQ ID NO: 2, residues 92-96) (m) A R C L; (SEQ ID NO: 12)(n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269) (o) F A RL I L; (portion of SEQ ID NO: 2, residues 264-269) (p) F A R L I;(portion of SEQ ID NO: 2, residues 264-268) (q) F A R L; (portion of SEQID NO: 2, residues 264-267) (r) H A R L I F; (portion of SEQ ID NO: 2,residues 292-297) (s) A R L I F; (portion of SEQ ID NO: 2, residues293-297) and homologs of such amino acid sequences.
 2. A compositioncomprising one or more nucleic acids according to claim 1 and apharmaceutically acceptable carrier therefor.
 3. A nucleic acid encodingan amino acid sequence selected from the group consisting of: (SEQ IDNOS 4-11, respectively, in order of appearance) (a) L H A R L CL A N F CG R N R V; (b) L A R L C LA N F C G N N N V; (c) C A R Y R T G H H A R LM; (d) H H A R L P L A N F C G; (e) R T G H H A R L C*L A N F C; (f) C ES A R Y R T G H H A R L C*; (g) D N T H H A R L I L; (h) S H H A R L IL; and homologs thereof.
 4. A composition comprising one or more nucleicacids according to claim 3 and a carrier therefor.
 5. A nucleic acidencoding the amino acid sequence A R L I, and comprising residuesencoding at least one and up to 25 additional amino acids flankingeither the 3′ or 5′ end of the peptide.
 6. A nucleic acid encoding theamino acid sequence H A R L and comprising residues encoding at leastone and up to 25 additional amino acids flanking either the 3′ or 5′ endof the peptide.
 7. A nucleic acid encoding the amino acid sequence F A RLand comprising residues encoding at least one and up to 25 additionalamino acids flanking either the 3′ or 5′ end of the peptide.
 8. Anucleic acid encoding the amino acid sequence A R Land comprisingresidues encoding at least one and up to 25 additional amino acidsflanking either the 3′ or 5′ end of the peptide.
 9. A nucleic acidencoding the amino acid sequence A R L C, and comprising residuesencoding at least one and up to 25 additional amino acids flankingeither the 3′ or 5′ end of the peptide.
 10. An antibody whichspecifically recognizes a peptide sequence having an amino acid sequenceselected from the group consisting of: (a) H H A R L; (portion of SEQ IDNO: 2, residues 291-295) (b) H A R L; (portion of SEQ ID NO: 2, residues292-295) (c) H A R L I; (portion of SEQ ID NO: 2, residues 292-296) (d)H A R L I L; (portion of SEQ ID NO: 2, residues 46-51) (e) H H A R L CL; (portion of SEQ ID NO: 2, residues 90-96) (f) A R L I L; (portion ofSEQ ID NO: 2, residues 47-51) (g) H H A R L I F; (portion of SEQ ID NO:2, residues 291-297) (h) T H A R L I L; (portion of SEQ ID NO: 2,residues 45-51) (i) A R L I; (portion of SEQ ID NO: 2, residues 47-50)(j) A R L; (k) H A R L C L; (portion of SEQ ID NO: 2, residues 91-96)(l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96) (m) A R C L;(SEQ ID NO: 12) (n) M F A R L I L; (portion of SEQ ID NO: 2, residues263-269) (o) F A R L I L; (portion of SEQ ID NO: 2, residues 264-269)(p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268) (q) F A R L;(portion of SEQ ID NO: 2, residues 264-267) (r) H A R L I F; (portion ofSEQ ID NO: 2, residues 292-297) (s) A R L I F; (portion of SEQ ID NO: 2,residues 293-297) and homologs thereof.
 11. An antibody whichspecifically recognizes a peptide sequence having an amino acid sequenceselected from the group consisting of: (SEQ ID NOS 4-11, respectively inorder of appearance) (a) L H A R L C L A N F C G R N R V; (b) L A R L CL A N F C G N N N V; (c) C A R Y R T G H HA R L M; (d) H H A R LP L A NF C G; (e) R T G H H A R L C*L A N F C; (f) C E S A R Y R T G H H A R LC*; (g) D N T H H A R L I L; (h) S H H A R L I L; and homologs thereof.12. An antibody which specifically recognizes a peptide sequence havingan amino acid sequence selected from the group consisting of: (a) A R LI; (portion of SEQ ID NO: 2, residues 47-50) (b) H A R L; (portion ofSEQ ID NO: 2, residues 91-94) (c) F A R L; (portion of SEQ ID NO: 2,residues 264-267) (d) A R L; and (e) A R L C, (SEQ ID NO: 12) whereinthe peptide comprises at least one and up to 25 additional amino acidsflanking either the 3′ or 5′ end of the peptide.
 13. A method forpurifying NTP from a biological sample comprising: (1) contacting abiological sample with one or more peptides having an amino acidsequence selected from the group consisting of: (a) H H A R L; (portionof SEQ ID NO: 2, residues 291-295) (b) H A R L; (portion of SEQ ID NO:2, residues 292-295) (c) H A R L I; (portion of SEQ ID NO: 2, residues292-296) (d) H A R L I L; (portion of SEQ ID NO: 2, residues 46-51) (e)H H A R L C L; (portion of SEQ ID NO: 2, residues 90-96) (f) A R L I L;(portion of SEQ ID NO: 2, residues 47-51) (g) H H A R L I F; (portion ofSEQ ID NO: 2, residues 291-297) (h) T H A R L I L; (portion of SEQ IDNO: 2, residues 45-51) (i) A R L I; (portion of SEQ ID NO: 2, residues47-50) (j) A R L; (k) H A R L C L; (portion of SEQ ID NO: 2, residues91-96) (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96) (m) A RC L; (SEQ ID NO: 12) (n) M F A R L I L; (portion of SEQ ID NO: 2,residues 263-269) (o) F A R L I L; (portion of SEQ ID NO: 2, residues264-269) (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268) (q)F A R L; (portion of SEQ ID NO: 2, residues 264-267) (r) H A R L I F;(portion of SEQ ID NO: 2, residues 292-297) (s) A R L I F; (portion ofSEQ ID NO: 2, residues 293-297) and homologs of such amino acidsequences; (2) isolating the resulting Harlil peptide/NTP conjugates;and (3) separating NTP from the one or more Harlil peptides to obtainpurified NTP.
 14. A method for purifying NTP from a biological samplecomprising: (1) contacting a biological sample with one or more peptideshaving an amino acid sequence selected from the group consisting of:(SEQ ID NOS 4-11, respectively, in order of appearance) (a) L H A R L CL A N F C G R N R V; (b) L A R L C L A N F C G N N N V; (c) C A R Y R TG H H A R L M; (d) H H A R L P L A N F C G; (e) R T G H H A R L C*L A NF C; (f) C E S A R Y R T G H H A R L C*; (g) D N T H HA R L I L; (h) S HH A R L I L; and homologs thereof; (2) isolating the resulting Harlilpeptide/NTP conjugates; and (3) separating NTP from the one or moreHarlil peptides to obtain purified NTP.
 15. A method for purifying NTPfrom a biological sample comprising: (a) contacting a biological samplewith one or more peptides having an amino acid sequence selected fromthe group consisting of: (i) A R L I; (portion of SEQ ID NO: 2, residues47-50) (ii) H A R L; (portion of SEQ ID NO: 2, residues 91-94) (iii) F AR L; (portion of SEQ ID NO: 2, residues 264-267) (iv) A R L; and (v) A RL C; (SEQ ID NO: 12) wherein the peptide comprises at least one and upto 25 additional amino acids flanking either the 3′ or 5′ end of thepeptide; (b) isolating the resulting Harlil peptide/NTP conjugates; and(c) separating NTP from the one or more Harlil peptides to obtainpurified NTP.
 16. A diagnostic test for determining the presence ofAlzheimer's Disease or other neurodegenerative disorder comprising: (1)contacting a biological sample with one or more peptides having an aminoacid sequence selected from the group consisting of: (a) H H A R L;(portion of SEQ ID NO: 2, residues 291-295) (b) H A R L; (portion of SEQID NO: 2, residues 292-295) (c) H A R L I; (portion of SEQ ID NO: 2,residues 292-296) (d) H A R L I L; (portion of SEQ ID NO: 2, residues46-51) (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 90-96) (f)A R L I L; (portion of SEQ ID NO: 2, residues 47-51) (g) H H A R L I F;(portion of SEQ ID NO: 2, residues 291-297) (h) T H A R L I L; (portionof SEQ ID NO: 2, residues 45-51) (i) A R L I; (portion of SEQ ID NO: 2,residues 47-50) (j) A R L; (k) H A R L C L; (portion of SEQ ID NO: 2,residues 91-96) (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96)(m) A R C L; (SEQ ID NO: 12) (n) M F A R L I L; (portion of SEQ ID NO:2, residues 263-269) (o) F A R L I L; (portion of SEQ ID NO: 2, residues264-269) (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268) (q)F A R L; (portion of SEQ ID NO: 2, residues 264-267) (r) H A R L I F;(portion of SEQ ID NO: 2, residues 292-297) (s) A R L I F; (portion ofSEQ ID NO: 2, residues 293-297) and homologs of such amino acidsequences; (2) determining the amount of NTP present in the sample; and(3) determining whether the amount of NTP present in the sample is abovea threshold amount indicative of the presence of Alzheimer's Disease orother neurodegenerative disorder.
 17. A diagnostic test for determiningthe presence of Alzheimer's Disease or other neurodegenerative disordercomprising: (1) contacting a biological sample with one or more peptideshaving an amino acid sequence selected from the group consisting of:(SEQ ID NOS 4-11, respectively, in order of appearance) (a) L H A R L CL A N F C G R N R V; (b) L A R L C L A N F C G N N N V; (c) C A R Y R TG H H A R L M; (d) H H A R L P L A N F C G; (e) R T G H H A R L C*L A NF C; (f) C E S A R Y R T G H H A R L C*; (g) D N T H H A R L I L; (h) SH H A R L I L; and homologs thereof; (2) determining the amount of NTPpresent in the sample; and (3) determining whether the amount of NTPpresent in the sample is above a threshold amount indicative of thepresence of Alzheimer's Disease or other neurodegenerative disorder. 18.A diagnostic test for determining the presence of Alzheimer's Disease orother neurodegenerative disorder comprising: (a) contacting a biologicalsample with one or more peptides having an amino acid sequence selectedfrom the group consisting of: (i) A R L I; (portion of SEQ ID NO: 2,residues 47-50) (ii) H A R L; (portion of SEQ ID NO: 2, residues 91-94)(iii) F A R L; (portion of SEQ ID NO: 2, residues 264-267) (iv) A R L;and (v) A R L C; (SEQ ID NO: 12) wherein the peptide comprises at leastone and up to 25 additional amino acids flanking either the 3′ or 5′ endof the peptide; (b) determining the amount of NTP present in the sample;and (c) determining whether the amount of NTP present in the sample isabove a threshold amount indicative of the presence of Alzheimer'sDisease or other neurodegenerative disorder.
 19. A diagnostic kit fordetermining the presence of Alzheimer's Disease or otherneurodegenerative disorder comprising: (1) one or more peptides havingan amino acid sequence selected from the group consisting of: (a) H H AR L; (portion of SEQ ID NO: 2, residues 291-295) (b) H A R L; (portionof SEQ ID NO: 2, residues 292-295) (c) H A R L I; (portion of SEQ ID NO:2, residues 292-296) (d) H A R L I L; (portion of SEQ ID NO: 2, residues46-51) (e) H H A R L C L; (portion of SEQ ID NO: 2, residues 90-96) (f)A R L I L; (portion of SEQ ID NO: 2, residues 47-51) (g) H H A R L I F;(portion of SEQ ID NO: 2, residues 291-297) (h) T H A R L I L; (portionof SEQ ID NO: 2, residues 45-51) (i) A R L I; (portion of SEQ ID NO: 2,residues 47-50) (j) A R L; (k) H A R L C L; (portion of SEQ ID NO: 2,residues 91-96) (l) A R L C L; (portion of SEQ ID NO: 2, residues 92-96)(m) A R C L; (SEQ ID NO: 12) (n) M F A R L I L; (portion of SEQ ID NO:2, residues 263-269) (o) F A R L I L; (portion of SEQ ID NO: 2, residues264-269) (p) F A R L I; (portion of SEQ ID NO: 2, residues 264-268) (q)F A R L; (portion of SEQ ID NO: 2, residues 264-267) (r) H A R L I F;(portion of SEQ ID NO: 2, residues 292-297) (s) A R L I F; (portion ofSEQ ID NO: 2, residues 293-297) and homologs of such amino acidsequences; and (2) suitable reagents.
 20. A diagnostic kit fordetermining the presence of Alzheimer's Disease or otherneurodegenerative disorder comprising: (1) one or more peptides havingan amino acid sequence selected from the group consisting of: (SEQ IDNOS 4-11, respectively, in order of appearance) (a) L H A R L C L A N FC G R N R V; (h) L A R L C L A N F C G N N N V; (c) C A R Y R T G H H AR L M; (d) H H A R L P L A N F C G; (e) R T G H H A R L C*L A N F C; (f)C E S A R Y R T G H H A R L C*; (g) D N T H H A R L I L; (h) S H H A R LI L; and homologs thereof; and (2) suitable reagents.
 21. A diagnostickit for determining the presence of Alzheimer's Disease or otherneurodegenerative disorder comprising: (a) one or more peptides havingan amino acid sequence selected from the group consisting of: (i) A R LI; (portion of SEQ ID NO: 2, residues 47-50) (ii) H A R L; (portion ofSEQ ID NO: 2, residues 91-94) (iii) F A R L; (portion of SEQ ID NO: 2,residues 264-267) (iv) H A R L I; (portion of SEQ ID NO: 2, residues292-296) (v) A R L C; (SEQ ID NO: 12) wherein the peptide comprises atleast one and up to 25 additional amino acids flanking either the 3′ or5′ end of the peptide; and (b) suitable reagents.
 22. A method of usinga peptide as an analogue for NTP in a therapeutic or diagnostic assay,comprising replacing NTP with the peptide in such an assay, wherein thepeptide has an amino acid sequence selected from the group consistingof: (a) H H A R L; (portion of SEQ ID NO: 2, residues 291-295) (b) H A RL; (portion of SEQ ID NO: 2, residues 292-295) (c) H A R L I; (portionof SEQ ID NO: 2, residues 292-296) (d) H A R L I L; (portion of SEQ IDNO: 2, residues 46-51) (e) H H A R L C L; (portion of SEQ ID NO: 2,residues 91-96) (f) A R L I L; (portion of SEQ ID NO: 2, residues 47-51)(g) H H A R L I F; (portion of SEQ ID NO: 2, residues 291-297) (h) T H AR L I L; (portion of SEQ ID NO: 2, residues 45-51) (i) A R L I; (portionof SEQ ID NO: 2, residues 47-50) (j) A R L; (k) H A R L C L; (portion ofSEQ ID NO: 2, residues 91-96) (l) A R L C L; (portion of SEQ ID NO: 2,residues 92-96) (m) A R C L; (SEQ ID NO: 12) (n) M F A R L I L; (portionof SEQ ID NO: 2, residues 263-269) (o) F A R L I L; (portion of SEQ IDNO: 2, residues 264-269) (p) F A R L I; (portion of SEQ ID NO: 2,residues 264-268) (q) F A R L; (portion of SEQ ID NO: 2, residues264-267) (r) H A R L I F; (portion of SEQ ID NO: 2, residues 292-297)(s) A R L I F; (portion of SEQ ID NO: 2, residues 293-297) and homologsof such amino acid sequences.
 23. A method of using a peptide as ananalogue for NTP in a therapeutic or diagnostic assay, comprisingreplacing NTP with the peptide in such an assay, wherein the peptide hasan amino acid sequence selected from the group consisting of: (SEQ IDNOS 4-11, respectively, in order of appearance) (a) L H A R L C L A N FC G R N R V; (b) L A R L C L A N F C G N N N V; (c) C A R Y R T G H H AR L M; (d) H H A R L P L A N F C G; (e) R T G H H A R L C*L A N F C; (f)C E S A R Y R T G H H A R L C*; (g) D N T H H A R L I L; (h) S H H A R LI L; and homologs thereof.
 24. A method of using a peptide as ananalogue for NTP in a therapeutic or diagnostic assay, comprisingreplacing NTP with the peptide in such an assay, wherein the peptide hasan amino acid sequence selected from the group consisting of: (a) A R LI; (portion of SEQ ID NO: 2, residues 47-50) (b) H A R L; (portion ofSEQ ID NO: 2, residues 91-94) (c) F A R L; (portion of SEQ ID NO: 2,residues 264-267) (d) A R L, and (e) A R L C; (SEQ ID NO: 12) whereinthe peptide comprises at least one and up to 25 additional amino acidsflanking either the 3′ or 5′ end of the peptide.
 25. A method of using apeptide as a trap material in a diagnostic or therapeutic assay, whereinthe peptide has an amino acid sequence selected from the groupconsisting of: (a) H H A R L; (portion of SEQ ID NO: 2, residues291-295) (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295) (c) HA R L I; (portion of SEQ ID NO: 2, residues 292-296) (d) H A R L I L;(portion of SEQ ID NO: 2, residues 46-51) (e) H H A R L C L; (portion ofSEQ ID NO: 2, residues 91-96) (f) A R L I L; (portion of SEQ ID NO: 2,residues 47-51) (g) H H A R L I F; (portion of SEQ ID NO: 2, residues291-297) (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51)(i) A R L I; (portion of SEQ ID NO: 2, residues 47-50) (j) A R L; (k) HA R L C L; (portion of SEQ ID NO: 2, residues 91-96) (l) A R L C L;(portion of SEQ ID NO: 2, residues 92-96) (m) A R C L; (SEQ ID NO: 12)(n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269) (o) F A RL I L; (portion of SEQ ID NO: 2, residues 264-269) (p) F A R L I;(portion of SEQ ID NO: 2, residues 264-268) (q) F A R L; (portion of SEQID NO: 2, residues 264-267) (r) H A R L I F; (portion of SEQ ID NO: 2,residues 292-297) (s) A R L I F; (portion of SEQ ID NO: 2, residues293-297) and homologs of such amino acid sequences.
 26. A method ofusing a peptide as a trap material in a diagnostic or therapeutic assay,wherein the peptide has an amino acid sequence selected from the groupconsisting of: (SEQ ID NOS 4-11, respectively, in order of appearance)(a) L H A R L C L A N F C G R N R V; (b) L A R L C L A N F C G N N N V;(c) C A R Y R T G H H A R L M; (d) H H A R L P L A N F C G; (e) R T G HH A R L C*L A N F C; (f) C E S A R Y R T G H H A R L C*; (g) D N T H H AR L I L; (h) S H H A R L I L; and homologs thereof.
 27. A method ofusing a peptide as a trap material in a diagnostic or therapeutic assay,wherein the peptide has an amino acid sequence selected from the groupconsisting of: (a) A R L I; (portion of SEQ ID NO: 2, residues 47-50)(b) H A R L; (portion of SEQ ID NO: 2, residues 91-94) (c) F A R L;(portion of SEQ ID NO: 2, residues 264-267) (d) A R L, and (e) A R L C;(SEQ ID NO: 12) wherein the peptide comprises at least one and up to 25additional amino acids flanking either the 3′ or 5′ end of the peptide.28. A method of isolating immunoglobulins from a sample using a peptidecomprising: (1) contacting a sample comprising immunoglobulins with atleast two peptides to allow for immunoglobulin/peptide interaction; and(2) isolating the resulting peptide/immunoglobulin conjugates, whereinthe peptide has an amino acid sequence selected from the groupconsisting of: (a) H H A R L; (portion of SEQ ID NO: 2, residues291-295) (b) H A R L; (portion of SEQ ID NO: 2, residues 292-295) (c) HA R L I; (portion of SEQ ID NO: 2, residues 292-296) (d) H A R L I L;(portion of SEQ ID NO: 2, residues 46-51) (e) H H A R L C L; (portion ofSEQ ID NO: 2, residues 91-96) (f) A R L I L; (portion of SEQ ID NO: 2,residues 47-51) (g) H H A R L I F; (portion of SEQ ID NO: 2, residues291-297) (h) T H A R L I L; (portion of SEQ ID NO: 2, residues 45-51)(i) A R L I; (portion of SEQ ID NO: 2, residues 47-50) (j) A R L; (k) HA R L C L; (portion of SEQ ID NO: 2, residues 91-96) (l) A R L C L;(portion of SEQ ID NO: 2, residues 92-96) (m) A R C L; (SEQ ID NO: 12)(n) M F A R L I L; (portion of SEQ ID NO: 2, residues 263-269) (o) F A RL I L; (portion of SEQ ID NO: 2, residues 264-269) (p) F A R L I;(portion of SEQ ID NO: 2, residues 264-268) (q) F A R L; (portion of SEQID NO: 2, residues 264-267) (r) H A R L I F; (portion of SEQ ID NO: 2,residues 292-297) (s) A R L I F; (portion of SEQ ID NO: 2, residues293-297) and homologs of such amino acid sequences.
 29. The method ofclaim 28, wherein the NTP peptide/immunoglobulin conjugates are isolatedby precipitation.
 30. The method of claim 28, wherein the NTPpeptide/immunoglobulin conjugates are isolated on an affinity column.31. The method of to claim 28, wherein the immunoglobulins aresubsequently purified.
 32. A method of isolating immunoglobulins from asample using a peptide comprising: (1) contacting a sample comprisingimmunoglobulins with at least two peptides to allow forimmunoglobulin/peptide interaction; and (2) isolating the resultingpeptide/immunoglobulin conjugates, wherein the peptide has an amino acidsequence selected from the group consisting of: (SEQ ID NOS 4-11,respectively, in order of appearance) (a) L H A R L C L A N F C G R N RV; (b) L A R L C L A N F C G N N N V; (c) C A R Y R T G H H A R L M; (d)H H A R L P L A N F C G; (e) R T G H H A R L C*L A N F C; (f) C E S A RY R T G H H A R L C*; (g) D N T H HA R L I L; (h) S H H A R L I L; andhomologs thereof.
 33. The method of claim 32, wherein thepeptide/immunoglobulin conjugates are isolated by precipitation.
 34. Themethod of claim 32, wherein the peptide/immunoglobulin conjugates areisolated on an affinity column.
 35. The method of to claim 32, whereinthe immunoglobulins are subsequently purified.
 36. A method of isolatingimmunoglobulins from a sample using a peptide comprising: (a) contactinga sample comprising immunoglobulins with at least two peptides to allowfor immunoglobulin/peptide interaction; and (b) isolating the resultingpeptide/immunoglobulin conjugates, wherein the peptide has an amino acidsequence selected from the group consisting of: (a) A R L I; (portion ofSEQ ID NO: 2, residues 47-50) (b) H A R L; (portion of SEQ ID NO: 2,residues 91-94) (c) F A R L; (portion of SEQ ID NO: 2, residues 264-267)(d) A R L; and (e) A R L C; (SEQ ID NO: 12) wherein the peptidecomprises at least one and up to 25 additional amino acids flankingeither the 3′ or 5′ end of the peptide.
 37. The method of claim 36,wherein the peptide/immunoglobulin conjugates are isolated byprecipitation.
 38. The method of claim 36, wherein thepeptide/immunoglobulin conjugates are isolated on an affinity column.39. The method according to claim 36, wherein the immunoglobulins aresubsequently purified.
 40. A method for preventing NTP interactingthrough the Harlil domains comprising blocking one or more Harlildomains by use of one or more Harlil peptides, Harlil peptide mimetics,antibodies to such a domain, or a combination thereof.